Anti-cancer treatments are often characterized by a familiar progression: at first tumors respond to a treatment, but cancer recurrence follows as tumor cells adapt to the therapy and resume unchecked proliferation. This adaptation of the tumor cells is frequently driven by epigenetic mechanisms to inactivate genes that confer sensitivity to the therapy and enhance the expression of genes that promote resistance.
BET proteins control the expression of several genes involved in the resistance to various anti-cancer treatments. BETi offer a unique opportunity to directly target resistance mechanisms and re-sensitize tumors to anti-cancer therapies. Zenith is focused on the clinical development of BETi in combination with selected therapies to take advantage of BETi’s unique capability to combat treatment-resistant cancers.
